Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Obsidian Therapeutics, Inc.

News headline image
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
From Obsidian Therapeutics, Inc.
Via Business Wire
Tickers GRTX
News headline image
Obsidian Therapeutics Appoints Julie Feder as Chief Financial Officer
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma in Ongoing Multicenter Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Obsidian Therapeutics to Present Preclinical Data Supporting Novel Application of cytoDRiVE® Platform at the American Society of Gene and Cell Therapy Annual Meeting
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Obsidian Therapeutics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Obsidian Therapeutics to Present Clinical Data from OBX-115, its Engineered TIL Cell Therapy, for Patients with Advanced Melanoma in Oral Presentation at the 2025 ASCO Annual Meeting
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Obsidian Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Obsidian Therapeutics to Present Preclinical Data Supporting OBX-115 and cytoDRiVE® Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Obsidian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OBX-115 for the Treatment of Advanced Melanoma
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Obsidian Therapeutics Announces FDA Fast Track Designation for OBX-115 for the Treatment of Advanced Melanoma
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Obsidian Therapeutics Announces Appointment of William Pao, M.D., Ph.D., to Board of Directors
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Obsidian Therapeutics Announces Additional OBX-115 Safety and Efficacy Data in Oral Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Obsidian Therapeutics Appoints Dana Alexander as Chief Technical Officer
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Obsidian Therapeutics to Present Clinical Data from OBX-115, its Engineered TIL Cell Therapy, for Patients with Advanced Solid Tumors in Oral Presentation at the 2024 ASCO Annual Meeting
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Obsidian Therapeutics Appoints Jeffrey Trigilio as Chief Financial Officer
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Obsidian Therapeutics Presents Positive 25-Week Median Study Follow-Up Safety and Efficacy Data from First-in-Human Study of OBX-115 in Advanced Melanoma at the American Association for Cancer Research Annual Meeting
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Obsidian Therapeutics Announces Oversubscribed $160.5 Million Series C Financing to Drive OBX-115 Clinical Development
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Obsidian Therapeutics Announces Clinical & Preclinical Presentations at the American Association of Cancer Research Annual Meeting
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Obsidian Therapeutics Announces Positive Interim Top-Line Clinical Data for OBX-115 Engineered TIL Cell Therapy in Advanced or Metastatic Melanoma Post-Anti-PD1 Therapy
From Obsidian Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.